Navigation Links
Neurological protein may hold the key to new treatments for depression
Date:11/29/2010

For Immediate Release November 29, 2010 (Toronto) Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.

The study published in this month's Nature Medicine found that coupling between two dopamine receptors was significantly elevated in the brains of people who had been diagnosed with major depression. "We identified a potential therapeutic target for development of novel anti-depressants." said Dr. Fang Liu, Principal Investigator and Senior Scientist in CAMH's Neuroscience Program and Associate Professor of Psychiatry at the University of Toronto. Working from this discovery, researchers sought to find a way to disrupt coupling between the two receptors in hopes that it would have an anti-depressant effect.

Using an autopsied brain study, Dr. Liu and her team initially found that coupling between two dopamine receptors was significantly elevated in the brains of people who had been diagnosed with major depression. They started by analyzing a specific dopamine signaling mechanism, the D1 and D2 receptor complex, to identify the sites where the two receptors bind together. With this information, they were able to generate a protein peptide to disrupt the binding of the two receptors. The peptide was then tested in animal models to compare the effects with existing anti-depressant medications.

"After we administered the peptide, we saw a marked improvement in depression-related behaviors. The improvement seen in the peptide group was equivalent to the improvement on traditional anti-depressant medication".

This peptide is an entirely new approach to treating depression, which has previously relied on medications that primarily block serotonin or norepinephrine transporters. These conventional antidepressant medications don't work for all patients, and can cause various side effects. "We are hopeful that our research will lead to new options for treatment that might have reduced side effects for patients with depression," Dr Liu stated.


'/>"/>

Contact: Michael Torres
media@camh.net
416-595-6015
Centre for Addiction and Mental Health
Source:Eurekalert

Related medicine news :

1. Elseviers BrainNavigator 3.0 reflects the next step in enhancing neurological research
2. NYU researchers identify new neurological deficit behind lazy eye
3. Scientists explain the neurological process for the recognition of letters and numbers
4. Team led by LA BioMed scientist develops novel approach to study neurological disorders
5. University Hospitals Neurological Institute earns Neuroscience Center of Excellence designation
6. University Hospitals Neurological Institute hosts international epilepsy colloquium
7. Rare disease in Amish children sheds light on common neurological disorders
8. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
9. Brain Science Institute announces license agreement to develop treatments for neurological disease
10. More Protein, Fewer Refined Carbs May Keep Weight Off
11. Protein found to predict brain injury in children on ECMO life support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Anxiety of older Americans over steep cost increases of ... a decade ago, according to The Senior Citizens League (TSCL). Since ... coping with rapidly rising costs. “The implications are chilling, particularly for people with ...
(Date:2/10/2016)... ... February 09, 2016 , ... According to a recent ... increase in the number of patients under the age of 30. According to Southern ... in their offices, and may indicate an overall shift in the rapidly growing social ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... to Medicaid beneficiaries who are diagnosed with autism spectrum disorder (ASD). Beginning Jan. ... Autism treatment using applied behavior analysis (ABA) is key to providing effective treatment ...
(Date:2/9/2016)... ... 09, 2016 , ... A new study from the Workers ... rates for a variety of medical services in Illinois as of 2015. ... Fee Schedule Rates in Illinois, are professional medical services, hospital outpatient and ...
(Date:2/9/2016)... ... 09, 2016 , ... Establishment Labs, a global breast implant and medical technology ... Board of Directors. , “We are honored to welcome David to our ... Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)...  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today ... and full year financial results on Tuesday, February 23, ... management will host a live audio webcast immediately following ... discuss fourth quarter and full year 2015 financial results ... for 2016 financial results. www.jazzpharmaceuticals.com .  Please ...
(Date:2/9/2016)... 9, 2016   AllCare Plus Pharmacy announced ... Seal of Approval ® for Home Care ... standards. The Gold Seal of Approval ® is ... to providing safe and effective care.  ... underwent a rigorous on-site survey in January 2016. The ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 The ... in 2014, and it is expected to grow with ... types, the glass prefilled syringes segment dominated the global ... --> --> The global ... significant rate, due to increasing geriatric population, increasing demand ...
Breaking Medicine Technology: